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Abstract
Background: A feasibility study was conducted to investigate whether an occupational at-risk cohort of women in Mwanza,
Tanzania are a suitable study population for future phase III vaginal microbicide trials.
Methodology/Principal Findings: 1573 women aged 16–54 y working in traditional and modern bars, restaurants, hotels,
guesthouses or as local food-handlers were enrolled at community-based reproductive health clinics, provided specimens
for HIV/STI and pregnancy testing, and asked to attend three-monthly clinical follow-up visits for 12-months. HIV positive
and negative women were eligible to enter the feasibility study and to receive free reproductive health services at any time.
HIV prevalence at baseline was 26.5% (417/1573). HIV incidence among 1156 sero-negative women attending at baseline
was 2.9/100PYs. Among 1020 HIV sero-negative, non-pregnant women, HIV incidence was 2.0/100PYs, HSV-2 incidence
12.7/100PYs and pregnancy rate 17.8/100PYs. Retention at three-months was 76.3% (778/1020). Among 771 HIV sero-
negative, non-pregnant women attending at three-months, subsequent follow-up at 6, 9 and 12-months was 83.7%, 79.6%,
and 72.1% respectively. Older women, those who had not moved home or changed their place of work in the last year, and
women working in traditional bars or as local food handlers had the highest re-attendance.
Conclusions/Significance: Women working in food outlets and recreational facilities in Tanzania and other parts of Africa
may be a suitable study population for microbicide and other HIV prevention trials. Effective locally-appropriate strategies
to address high pregnancy rates and early losses to follow-up are essential to minimise risk to clinical trials in these settings.
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Introduction
In many developed and developing countries, HIV prevention
trials are usually undertaken among vulnerable, disadvantaged
communities at high-risk of HIV and STIs, where HIV incidence
rates make randomised controlled clinical trials feasible[1,2] but
where poverty and social exclusion mean ethical considerations
are paramount[3,4]. Such populations may include female sex
workers, injecting drug users, men who have sex with men, prison
inmates and the homeless[5,6,7,8,9,10,11,12,13,14].
There are considerable ethical and logistical challenges to
consider when planning HIV prevention trials in such populations,
for example, the need to develop effective locally-appropriate
informed consent procedures[4,15,16,17,18,19], of ensuring that
trial participation does not exacerbate stigma, vulnerability or
social harm[20,21,22]; and to ensure that appropriate locally-
agreed standards of clinical care are made available to trial
participants, particularly those who seroconvert during the trial or
who are HIV positive at screening[23,24,25].
Recruiting and retaining participants from high-risk cohorts is
often problematic. In many settings it is difficult to access and
meaningfully engage with vulnerable groups in the communi-
ty[11,12]. Providing accurate information about trial objectives
and procedures; dispelling fears around disclosure and confiden-
tiality; and reducing distrust and suspicion between potential
participants and external researchers may therefore be difficult,
and may hinder trial enrolment. High mobility is common in
many vulnerable groups, which makes tracing those who default
from follow-up difficult, necessitating the use of community
fieldworkers or peer educators[26]. Volunteers from vulnerable
groups may be reluctant to attend established health services due
to travel and opportunity costs and the way in which they are
treated by health centre staff so that it is often necessary to
establish community-based study clinics, which may need to
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10661operate at unusual hours or at weekends in order to encourage
potential participants to attend[4,12,26]. In addition to these
considerations, researchers planning vaginal microbicide trials also
need to take into account pregnancy rates and the prevalence and
nature of intravaginal hygiene practices in any proposed study
population.
The search for female-controlled methods of HIV prevention
has led to a concerted international effort to develop vaginal
microbicides: topical chemical agents, which when administered
vaginally prior to sexual intercourse would prevent HIV and
ideally other sexually transmitted infections (STIs)[27,28].
Mwanza is one of six centres in Sub-Saharan Africa participating
in the Microbicides Development Programme (MDP), an
international partnership for the development of vaginal micro-
bicides for HIV prevention, funded by the UK Department for
International Development and Medical Research Council
(MRC)[29].
In preparation for the MDP301 randomised placebo-controlled
efficacy and safety trial of the candidate vaginal microbicide
PRO2000/5 Gel (Indevus Pharmaceuticals, USA), we carried out
a feasibility study in an occupational cohort of women at high-risk
of HIV/STIs in ten administrative wards in Mwanza City,
northern Tanzania between July 2002 and December 2004.
Women working in food and recreational facilities, including
modern bars, traditional bars (vilabu or pombe shops), restaurants,
hotels, guesthouses, groceries and as informal food vendors
(mamalishe), were eligible to participate. In Tanzania, high rates
of HIV and STIs have been reported among women working in
such facilities in areas situated along major transit
routes[30,31,32,33] and in commercial centres adjacent to
newly-established goldmines[34,35]. Some women in this occu-
pational group are reported to periodically supplement their
income through transactional sex[35,36] and, although not
necessarily perceived as commercial sex workers within the wider
community, are nonetheless at increased risk of STIs and HIV
infection[31,33,34].
The objectives of the feasibility study were to: test the feasibility
of recruiting and retaining sufficient numbers of women for a
subsequent microbicides trial; assess baseline HIV and STI
prevalence, HIV incidence and pregnancy rates; investigate
methods for improving the reliability and validity of reported
sexual behaviour data including condom use and intravaginal
practices; and investigate the acceptability of vaginal microbicide
gels among women and their sexual partners.
The baseline socio-demographic and behavioural characteristics
of 1573 participants enrolled in the feasibility study and the factors
associated with loss to follow-up at three-months have previously
been described[37]. In this paper, we present data on cohort
retention, factors associated with loss to follow-up, and HIV, STI
and pregnancy incidence over 12 months of follow-up among
initially HIV sero-negative, non-pregnant women who would be
eligible for future phase III HIV prevention trials. We use the
findings to examine whether this is a suitable study population in
which to conduct such clinical trials in Africa.
Methods
Study design
The design of the study, study population and laboratory
methods have been described previously[37]. Briefly, following
participatory community mobilisation and mapping activities,
weekly community-based reproductive health clinics were estab-
lished in selected guesthouses in ten administrative wards in
Mwanza City, northern Tanzania by October 2002. In order to
avoid exacerbating stigma, social exclusion or harm as a result of
study participation and to investigate the feasibility of recruiting
women for a variety of future HIV-related clinical research
activities both HIV positive and negative women were eligible to
participate in the Mwanza feasibility study. The study design did
not therefore include a preliminary screening assessment (e.g. to
confirm negative HIV and pregnancy status) and participants were
directly enrolled at their first clinic visit.
Study procedures and investigations
Free reproductive health services, including syndromic man-
agement of STIs, family planning, health education, and voluntary
HIV counselling and testing (VCT) were provided. Participants
were asked to attend a study clinic every three months, when a
study nurse collected demographic and sexual behaviour infor-
mation using a pre-tested questionnaire in Swahili. A gynaeco-
logical examination was offered at entry and six monthly clinical
follow-up visits when vaginal swabs for bacterial vaginosis and
Trichomonas vaginalis, cervical swabs for Neisseria gonorrhoeae and
Chlamydia trachomatis, urine for pregnancy testing and venous blood
for HIV, syphilis and Herpes simplex type-2 (HSV-2) serology were
also collected. Women with symptoms and clinical signs of STIs
were managed according to Tanzanian national syndromic
management guidelines[38]. Women were encouraged to use the
free drop-in reproductive health service at any time between
booked appointments.
Ethics
Ethical clearance was obtained from the National Medical
Research Coordinating Committee in Tanzania and the Ethics
Committee of the London School of Hygiene and Tropical
Medicine, UK. Written informed consent (signature or witnessed
thumbprint) was obtained from all participants prior to enrolment.
Statistical Methods
Data were double-entered and verified. We calculated atten-
dance rates at three-monthly visits for three distinct groups: the
complete cohort of HIV positive and negative women attending a
baseline clinic visit (N=1573); all HIV-negative, non-pregnant
women from this complete baseline cohort (N=1020); and all
HIV-negative, non-pregnant women who attended a first follow-
up visit at three-months (N=771) (Figure 1). The sub-cohorts of
1020 and 771 subjects represent women who would be considered
broadly eligible for entry into a phase III vaginal microbicide trial
such as MDP301. Due to the lack of a screening visit in the
Mwanza feasibility study design we considered that retention rates
among the sub-cohort of 771 ‘eligible’ women who re-attended for
the first follow-up visit were more likely to be predictive of future
retention in a phase III clinical trial in this setting than in the
larger sub-cohort of 1020 women or the complete cohort of 1573
subjects.
We present selected characteristics of ‘eligible’ women, stratified
by the type of facility in which they are employed (mamalishe or
pombe shop, guesthouse or hotel, restaurant or bar or grocery).
We calculated the baseline prevalence and incidence of pregnancy
and serological markers including HIV; and the prevalence of
STIs and aspects of sexual behaviour at each follow-up visit. We
tested for trends in prevalence over time by fitting a longitudinal
logistic regression model for each STI and sexual behaviour
outcome, which allowed for correlations induced by repeat visits of
each participant. We included time in each model by including
visit attendance (baseline then three-monthly follow-up over 12-
months), and assessed its effect using a likelihood ratio test.
Microbicide Trials in Africa
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created a new variable for the number of follow-up visits attended
after the three-month clinic visit (‘attendance’). Each participant
could therefore miss one, two, or three subsequent visits. We
treated this outcome variable as ordinal and used ordinal logistic
regression to examine factors associated with re-attendance, so
that an odds ratio .1.0 was associated with a better attendance
profile. Models were adjusted for age, clinic site, facility type, and
other variables that were statistically significant (P,0.05). For this
regression analysis we constructed two composite variables with
three levels (low, moderate and high): ‘travel’ based on time away
from home, and ‘permanence’ based on moving home or job in
the previous year. We used Stata for all analyses (Version 10,
StataCorp LP, College Station, Texas, US).
Results
General characteristics of the study population
Participatory community mapping conducted in March 2002
showed that there were around 2494 women working in 953 food
and recreational facilities in ten administrative wards in Mwanza
City[37]. Of 1573 women attending a first clinic visit, 1020
(64.8%) were HIV sero-negative, had a negative urine pregnancy
test and would have been considered broadly eligible for
enrolment into a future vaginal microbicide trial (Table 1).
Around 24% (242/1020) of women in this sub-population failed to
re-attend a second clinic visit at three-months; subsequent
retention was also poor in this group. Of the 778 women who
re-attended at three-months, 771 would have been considered
eligible for enrolment into a future microbicide trial based on the
above criteria. Re-attendance in this sub-population at subsequent
three-monthly clinical follow-up visits was 83.7%, 79.6% and
72.1%.
The socio-demographic characteristics of the 1020 eligible
women attending at baseline and the 771 eligible women
attending at three-months were broadly similar in terms of facility
type, level of education, literacy and ethnicity (Table 2) and
reflected the distribution observed in the full feasibility study
cohort of 1573 women[37]. Comparing the 242 women who did
not attend at three-months with the 778 women who did, women
who did not re-attend tended to be younger (difference in mean
age 4.9 y; p,0.001); were less likely to be married (p,0.001); had
travelled more frequently in the three-months before recruitment
(difference in travel scores p=0.01); and were more mobile in
terms of recent changes in accommodation and place of work
(difference in permanence scores p,0.001).
Prevalence and incidence of pregnancy, HIV and STI
Baseline HIV and STI prevalences have been reported
elsewhere[37] but in brief, among the 1573 women who attended
a first clinic visit, the prevalence of HIV was 26.5%; pregnancy
9.6%; HSV-2 infection 74.1%; active syphilis (TPPA+/RPR+)
10.1%, bacterial vaginosis 50.7%; gonorrhoea 5.3%; chlamydia
Figure 1. Data analysis summary by sub-cohort, MDP Mwanza Feasibility Study.
doi:10.1371/journal.pone.0010661.g001
Table 1. Re-attendance among women eligible to enrol in a
future microbicide trial.
Attendance
Visit
Full
cohort
Eligible and
attending at
baseline
1
Eligible and
attending at
3 mo.
2
Baseline 1573 1020
3 month 1165 (74.1%) 778 (76.3%) 771
6 month 1079 (68.6%) 726 (71.2%) 645 (83.7%)
9 month 1006 (64.0%) 680 (66.7%) 614 (79.6%)
12 month 905 (57.5%) 607 (59.5%) 556 (72.1%)
Overall attendance rate
at 12-months (95% CI)
3
66.0%
(64.9–67.2)
68.4%
(67.0–69.8)
78.5%
(76.7–80.1)
1 At baseline, there were 1573 attendees. Of these 1156 (73.5%) were HIV
negative, 1409 (89.6%) were not pregnant, and 1020 (64.8%) were both HIV
negative and not-pregnant and therefore met broad eligibility criteria for
enrolment into a future microbicide trial.
2 At the 3-month clinic visit, 778/1020 (76.3%) women originally considered
eligible for enrolment re-attended; 7/778 women sero-converted between
baseline and 3 mo. visits leaving a total of 771 ‘eligible’ women at 3-months.
3 Attendance = % of all possible follow-up visits that were actually attended.
doi:10.1371/journal.pone.0010661.t001
Microbicide Trials in Africa
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10661T
a
b
l
e
2
.
S
e
l
e
c
t
e
d
s
o
c
i
o
-
d
e
m
o
g
r
a
p
h
i
c
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
e
l
i
g
i
b
l
e
s
u
b
-
c
o
h
o
r
t
s
a
t
b
a
s
e
l
i
n
e
(
n
=
1
0
2
0
)
a
n
d
3
m
o
.
v
i
s
i
t
(
n
=
7
7
1
)
.
B
a
s
e
l
i
n
e
(
n
=
1
0
2
0
)
3
-
m
o
n
t
h
s
(
n
=
7
7
1
)
M
a
m
a
l
i
s
h
e
/
P
o
m
b
e
(
n
=
6
5
4
;
6
4
.
1
%
)
G
u
e
s
t
h
o
u
s
e
/
H
o
t
e
l
(
n
=
1
6
4
;
1
6
.
1
%
)
R
e
s
t
a
u
r
a
n
t
/
B
a
r
/
G
r
o
c
e
r
y
(
n
=
2
0
2
;
1
9
.
8
%
)
A
l
l
(
N
=
1
0
2
0
)
M
a
m
a
l
i
s
h
e
/
P
o
m
b
e
(
n
=
5
1
7
;
6
7
.
1
%
)
G
u
e
s
t
h
o
u
s
e
/
H
o
t
e
l
(
n
=
1
1
5
;
1
4
.
9
%
)
R
e
s
t
a
u
r
a
n
t
/
B
a
r
/
G
r
o
c
e
r
y
(
n
=
1
3
9
;
1
8
.
0
%
)
A
l
l
(
N
=
7
7
1
)
A
g
e
(
m
e
a
n
,
S
D
)
3
0
.
8
(
8
.
7
)
2
7
.
1
(
6
.
5
)
2
7
.
1
(
7
.
0
)
2
9
.
5
(
8
.
2
)
3
1
.
9
(
8
.
7
)
2
8
.
2
(
6
.
8
)
2
8
.
0
(
7
.
0
)
3
0
.
6
(
8
.
4
)
A
g
e
(
y
e
a
r
s
)
1
,
2
0
4
9
(
7
.
5
%
)
1
6
(
9
.
8
%
)
2
0
(
9
.
9
%
)
8
5
(
8
.
3
%
)
2
5
(
4
.
8
%
)
6
(
5
.
2
%
)
1
0
(
7
.
2
%
)
4
1
(
5
.
3
%
)
2
0
–
2
4
1
2
4
(
1
9
.
0
%
)
5
0
(
3
0
.
5
%
)
7
1
(
3
5
.
2
%
)
2
4
5
(
2
4
.
0
%
)
8
9
(
1
7
.
3
%
)
3
4
(
2
9
.
6
%
)
4
1
(
2
9
.
5
%
)
1
6
4
(
2
1
.
3
%
)
2
5
–
3
4
2
7
4
(
4
2
.
0
%
)
7
6
(
4
6
.
3
%
)
8
6
(
4
2
.
6
%
)
4
3
6
(
4
2
.
8
%
)
2
1
3
(
4
1
.
3
%
)
5
4
(
4
7
.
0
%
)
6
9
(
4
9
.
6
%
)
3
3
6
(
4
3
.
6
%
)
3
5
+
2
0
6
(
3
1
.
6
%
)
2
2
(
1
3
.
4
%
)
2
5
(
1
2
.
4
%
)
2
5
3
(
2
4
.
8
%
)
1
8
9
(
3
6
.
6
%
)
2
1
(
1
8
.
3
%
)
1
9
(
1
3
.
7
%
)
2
2
9
(
2
9
.
7
%
)
E
d
u
c
a
t
i
o
n
P
r
i
m
a
r
y
i
n
c
o
m
p
l
e
t
e
1
8
4
(
2
8
.
1
%
)
2
2
(
1
3
.
4
%
)
3
7
(
1
8
.
3
%
)
2
4
3
(
2
3
.
8
%
)
1
4
4
(
2
7
.
9
%
)
1
6
(
1
3
.
9
%
)
2
5
(
1
8
.
0
%
)
1
8
5
(
2
4
.
0
%
)
P
r
i
m
a
r
y
c
o
m
p
l
e
t
e
4
2
2
(
6
4
.
5
%
)
9
4
(
5
7
.
3
%
)
1
4
2
(
7
0
.
3
%
)
6
5
8
(
6
4
.
5
%
)
3
3
6
(
6
5
.
0
%
)
6
3
(
5
4
.
8
%
)
9
4
(
6
7
.
6
%
)
4
9
3
(
6
3
.
9
%
)
S
e
c
o
n
d
a
r
y
3
0
(
4
.
6
%
)
4
3
(
2
6
.
2
%
)
1
9
(
9
.
4
%
)
9
2
(
9
.
0
%
)
2
1
(
4
.
1
%
)
3
3
(
2
8
.
7
%
)
1
6
(
1
1
.
5
%
)
7
0
(
9
.
1
%
)
O
t
h
e
r
1
8
(
2
.
8
%
)
5
(
3
.
1
%
)
4
(
2
.
0
%
)
2
7
(
2
.
7
%
)
1
6
(
3
.
1
%
)
3
(
2
.
6
%
)
4
(
2
.
9
%
)
2
3
(
3
.
0
%
)
M
a
r
i
t
a
l
s
t
a
t
u
s
M
a
r
r
i
e
d
3
4
2
(
5
2
.
3
%
)
2
3
(
1
4
.
0
%
)
3
8
(
1
8
.
8
%
)
4
0
3
(
3
9
.
5
%
)
2
8
2
(
5
4
.
6
%
)
1
6
(
1
3
.
9
%
)
2
6
(
1
8
.
7
%
)
3
2
4
(
4
2
.
0
%
)
S
e
p
a
r
a
t
e
d
/
d
i
v
o
r
c
e
d
/
w
i
d
o
w
e
d
2
1
8
(
3
3
.
3
%
)
7
8
(
4
7
.
6
%
)
9
7
(
4
8
.
0
%
)
3
9
3
(
3
8
.
5
%
)
1
7
7
(
3
4
.
2
%
)
5
5
(
4
7
.
8
%
)
6
7
(
4
8
.
2
%
)
2
9
9
(
3
8
.
8
%
)
S
i
n
g
l
e
9
4
(
1
4
.
4
%
)
6
3
(
3
8
.
4
%
)
6
7
(
3
3
.
2
%
)
2
2
4
(
2
2
.
0
%
)
5
8
(
1
1
.
2
%
)
4
4
(
3
8
.
3
%
)
4
6
(
3
3
.
1
%
)
1
4
8
(
1
9
.
2
%
)
E
t
h
n
i
c
g
r
o
u
p
S
u
k
u
m
a
2
3
1
(
3
5
.
3
%
)
6
3
(
3
8
.
4
%
)
6
3
(
3
1
.
2
%
)
3
5
7
(
3
5
.
0
%
)
1
8
5
(
3
5
.
8
%
)
4
1
(
3
5
.
7
%
)
4
3
(
3
0
.
9
%
)
2
6
9
(
3
4
.
9
%
)
O
t
h
e
r
4
2
3
(
6
4
.
7
%
)
1
0
1
(
6
1
.
6
%
)
1
3
9
(
6
8
.
8
%
)
6
6
3
(
6
5
.
0
%
)
3
3
2
(
6
4
.
2
%
)
7
4
(
6
4
.
4
%
)
9
6
(
6
9
.
1
%
)
5
0
2
(
6
5
.
1
%
)
L
i
t
e
r
a
c
y
N
o
1
2
4
(
1
9
.
0
%
)
1
6
(
9
.
8
%
)
2
5
(
1
2
.
4
%
)
1
6
5
(
1
6
.
2
%
)
1
0
1
(
1
9
.
5
%
)
1
2
(
1
0
.
4
%
)
1
4
(
1
0
.
1
%
)
1
2
7
(
1
6
.
5
%
)
Y
e
s
5
3
0
(
8
1
.
0
%
)
1
4
8
(
9
0
.
2
%
)
1
7
7
(
8
7
.
6
%
)
8
5
5
(
8
3
.
8
%
)
4
1
6
(
8
0
.
5
%
)
1
0
3
(
8
9
.
6
%
)
1
2
5
(
8
9
.
9
%
)
6
4
4
(
8
3
.
5
%
)
T
r
a
v
e
l
2
L
o
w
4
8
8
(
7
4
.
6
%
)
8
8
(
5
3
.
7
%
)
1
1
4
(
5
7
.
0
%
)
6
9
0
(
6
7
.
8
%
)
3
8
3
(
7
4
.
1
%
)
6
8
(
5
9
.
1
%
)
7
6
(
5
5
.
1
%
)
5
2
7
(
6
8
.
4
%
)
M
o
d
e
r
a
t
e
1
4
6
(
2
2
.
3
%
)
6
0
(
3
6
.
6
%
)
6
3
(
3
1
.
5
%
)
2
6
9
(
2
6
.
4
%
)
1
2
1
(
2
3
.
4
%
)
3
9
(
3
3
.
9
%
)
4
8
(
3
4
.
8
%
)
2
0
8
(
2
7
.
0
%
)
H
i
g
h
2
0
(
3
.
1
%
)
1
6
(
9
.
8
%
)
2
3
(
1
1
.
5
%
)
5
9
(
5
.
8
%
)
1
3
(
2
.
5
%
)
8
(
7
.
0
%
)
1
4
(
1
0
.
1
%
)
3
5
(
4
.
6
%
)
P
e
r
m
a
n
e
n
c
e
3
H
i
g
h
3
1
5
(
4
8
.
2
%
)
4
5
(
2
7
.
6
%
)
4
5
(
2
2
.
3
%
)
4
0
5
(
3
9
.
8
%
)
2
6
9
(
5
2
.
1
%
)
3
4
(
2
9
.
8
%
)
3
9
(
2
8
.
1
%
)
3
4
2
(
4
4
.
5
%
)
M
o
d
e
r
a
t
e
1
6
5
(
2
5
.
3
%
)
5
1
(
3
1
.
3
%
)
6
3
(
3
1
.
2
%
)
2
7
9
(
2
7
.
4
%
)
1
2
7
(
2
4
.
6
%
)
3
5
(
3
0
.
7
%
)
4
4
(
3
1
.
7
%
)
2
0
6
(
2
6
.
8
%
)
L
o
w
1
7
3
(
2
6
.
5
%
)
6
7
(
4
1
.
1
%
)
9
4
(
4
6
.
5
%
)
3
3
4
(
3
2
.
8
%
)
1
2
0
(
2
3
.
3
%
)
4
5
(
3
9
.
5
%
)
5
6
(
4
0
.
3
%
)
2
2
1
(
2
8
.
7
%
)
1
O
n
e
p
a
r
t
i
c
i
p
a
n
t
w
i
t
h
n
o
r
e
c
o
r
d
e
d
a
g
e
;
2
T
r
a
v
e
l
i
n
t
h
e
t
h
r
e
e
m
o
n
t
h
s
p
r
e
c
e
d
i
n
g
b
a
s
e
l
i
n
e
c
l
i
n
i
c
v
i
s
i
t
w
a
s
c
a
t
e
g
o
r
i
s
e
d
a
s
:
L
o
w
(
z
e
r
o
n
i
g
h
t
s
a
w
a
y
f
r
o
m
h
o
m
e
)
,
M
o
d
e
r
a
t
e
(
$
1
n
i
g
h
t
b
u
t
l
e
s
s
t
h
a
n
o
n
e
c
o
n
t
i
n
u
o
u
s
w
e
e
k
a
w
a
y
f
r
o
m
h
o
m
e
)
a
n
d
H
i
g
h
(
$
1
c
o
n
t
i
n
u
o
u
s
w
e
e
k
a
w
a
y
f
r
o
m
h
o
m
e
o
n
o
n
e
o
r
m
o
r
e
o
c
c
a
s
i
o
n
s
)
;
3
P
e
r
m
a
n
e
n
c
e
o
f
h
o
m
e
a
n
d
w
o
r
k
p
l
a
c
e
l
o
c
a
t
i
o
n
w
a
s
c
a
t
e
g
o
r
i
s
e
d
a
s
:
H
i
g
h
(
l
i
v
e
d
i
n
t
h
e
s
a
m
e
h
o
u
s
e
a
n
d
w
o
r
k
e
d
a
t
t
h
e
s
a
m
e
f
a
c
i
l
i
t
y
d
u
r
i
n
g
t
h
e
p
a
s
t
y
e
a
r
)
;
M
o
d
e
r
a
t
e
(
l
i
v
e
d
o
r
w
o
r
k
e
d
a
t
t
h
e
s
a
m
e
l
o
c
a
t
i
o
n
f
o
r
,
1
y
e
a
r
a
n
d
m
o
v
e
d
h
o
u
s
e
n
o
m
o
r
e
t
h
a
n
o
n
c
e
i
n
t
h
e
p
r
e
v
i
o
u
s
y
e
a
r
)
;
L
o
w
(
l
i
v
e
d
o
r
w
o
r
k
e
d
a
t
t
h
e
s
a
m
e
l
o
c
a
t
i
o
n
f
o
r
,
1
y
e
a
r
a
n
d
m
o
v
e
d
h
o
u
s
e
t
w
i
c
e
o
r
m
o
r
e
i
n
t
h
e
p
r
e
v
i
o
u
s
y
e
a
r
)
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
1
0
6
6
1
.
t
0
0
2
Microbicide Trials in Africa
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e106615.7% and trichomoniasis 12.3%. HIV prevalence at baseline
increased with age, was lower among local food-handlers
(mamalishe) and women working in traditional bars, married
women and those with fewer sexual partners, and was associated
with HSV-2 infection and bacterial vaginosis.
The incidence of HIV among all women who were sero-
negative at baseline (1156/1573) was 2.9 per 100 person-years
(PYs) (95%CI:1.9–4.3). HIV incidence among mamalishe/pombe
shop workers (2.0/100PYs [95%CI:1.1–3.6]) and guesthouse/
hotel workers (3.5/100PYs [95%CI:1.3–9.3]) was lower than
among restaurant/bar workers (5.7/100PYs [95%CI:2.9–11.4]).
HIV incidence was highest in those aged 25–34years (4.3/100PYs
[95%CI:2.6–7.1]) among whom 15 of the 23 (65%) sero-
conversions observed in this sub-population occurred (data not
shown).
In the sub-cohort of 1020 eligible (HIV sero-negative, non-
pregnant) women who attended at baseline the incidence of HIV
was 2.0/100PYs (Table 3). HIV incidence among mamalishe/
pombe shop workers (1.6/100PYs) and guesthouse/hotel workers
(1.0/100PYs) was again lower than among restaurant/bar workers
(4.1/100PYs). The incidence of pregnancy in this sub-cohort was
17.8/100PYs and HSV-2 incidence 12.7/100PYs.
The prevalence of gonorrhoea, chlamydia and bacterial
vaginosis was significantly lower at 6 and 12-months compared
to baseline (Table 4). The prevalence of trichomoniasis also fell
from 12.3% at baseline to 6.5% at 12-months (p=0.09).
Sexual behaviour, condom use and contraception
The proportion of women reporting two or more sexual
partners at each clinical follow-up visit was significantly less than at
baseline (p,0.001), whilst consistent condom use with non-regular
partners was significantly higher at each time point (p,0.001;
Table 4). There were no significant changes observed in reported
condom use with regular partner. The prevalence of reported
vaginal cleansing was significantly higher during follow-up than at
baseline (p,0.001). A significant reduction was seen in the
proportion of women who perceived themselves to be at high risk
of HIV acquisition (p=0.001).
Among the 1573 women attending a first clinic visit, anal sex in
the previous three-months was reported by #1% at baseline, 6
and 12-months (data not shown).
Reported intent to become pregnant was significantly lower at
each follow-up visit than at baseline (p,0.001) with a significant
increase also observed in contraceptive prevalence (all methods
combined) (p,0.001). However, there was no significant change in
the proportion of women using highly effective contraceptive
methods (pills/injection/IUCD) (p=0.08) and the proportion of
women with positive urine pregnancy tests at baseline, 6 and 12-
months were similar (9.7, 10.0 and 9.3% respectively).
Cohort retention
Among the 771 eligible women who attended at three-months,
older women, those working in pombe shops or as mamalishe, those
reporting fewer sexual partners in the last three months and
women who were less mobile in terms of recent changes in
accommodation and place of work had a significantly greater odds
of re-attendance (Table 5). The adjusted odds of re-attendance
were five times higher in women aged $35years than those aged
,20years. Marital status, ethnicity, education level and literacy
were not associated with re-attendance (data not shown).
Discussion
Researchers in a variety of settings have conducted prepared-
ness or feasibility studies in order to assess the suitability of
potential study populations for future HIV prevention tri-
als[5,6,7,8,10,11,12,13]. Feasibility is critically dependant on a
number of key epidemiological factors[1,2]. HIV incidence rates
need to be sufficiently high to support large scale clinical trials;
cost-effective strategies for recruiting and retaining sufficient
numbers of subjects need to be available or developed; the impact
of effective risk reduction counseling and syndromic STI
management on HIV and STI rates during follow up need to be
taken into account; the ability to collect reliable, valid sexual
behaviour data assessed; and key risks to future clinical trials, such
as high pregnancy rates and differential losses to follow-up of those
Table 3. Prevalence and incidence of pregnancy, HIV and STIs among eligible women attending at baseline (n=1020).
Baseline (n=1020)
Pregnancy and
serological markers
Prevalent
cases
Participants
tested
Baseline
Prevalence
New
Cases
Person
years (PYs)
incidence rate
per 100 PYs (95% CI)
1
Pregnancy 0 1020 -
2 111 623.8 17.8 (14.8–21.4)
Serology
HIV 0 1020 -
2 14 713.8 2.0 (1.2–3.3)
HSV-2 703 1019 69.0% 19 150.2 12.7 (8.1–19.8)
TPPA+/RPR+
3 98 1018 9.6% 14 598.0 2.3 (1.4–4.0)
HIV incidence by facility type
Mamalishe/pombe 0 654 -
2 8 493.5 1.6 (0.8–3.2)
Guesthouse/hotel 0 164 -
2 1 96.1 1.0 (0.1–7.4)
Restaurant/bar/grocery 0 202 -
2 5 123.3 4.1 (1.7–9.7)
1. Participants were tested for each incident endpoint at baseline, and at three-monthly intervals during follow-up. Incidence was calculated as the number of new
cases divided by the total time in years that participants remained in the study without the incident endpoint of interest. Following standard practice, participants were
considered censored at their last recorded study visit.
2. Pregnancy and HIV seropositive status were initial study exclusion criteria. By definition, HIV prevalence was therefore zero among 1020 eligible women at baseline.
3. Incident cases were defined as those who tested positive for both TPPA and RPR for the first time during follow-up and exclude women with active syphilis (TPPA+
and RPR+) at baseline.
doi:10.1371/journal.pone.0010661.t003
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strategies developed. There are also additional issues specific to
vaginal microbicide trials that need to be taken into account such
as product acceptability (among participants and their sexual
partners)[39,40,41,42,43] and intravaginal practices[44,45].
During this microbicide trial feasibility study in northern
Tanzania, we were able to recruit and retain a large number of
participants from a high-risk occupational cohort of women known
to engage in transactional sex. Of the 2494 potential participants
identified during community mapping, 1573 (63.1%) attended a
first clinic visit and were enrolled directly into the feasibility
cohort. Among a sub-cohort of 1020 HIV negative non-pregnant
women attending a first visit who would have been considered
broadly eligible to enroll in a microbicide trial, there were
significant early losses to follow-up. Subsequent retention among a
sub-cohort of 771 eligible women who attended a second clinic
visit was however more satisfactory. Comparable retention rates
have been reported in similar high-risk occupational groups and in
Table 4. Prevalence of STIs, pregnancy, contraception and reported sexual behaviour at baseline and scheduled follow-up visits
among 1020 potential trial participants.
Baseline
(n=1020)
3 mo.
(n=778)
6 mo.
(n=726)
9 mo.
(n=680)
12 mo.
(n=607)
Odds Ratio/
P-value
1
Genital swabs
N gonorrhoeae (NG) 5.3% (52/986) - 1.7% (11/631) - 1.7% (7/433) 0.66 (0.54–
0.82) p,0.001
C trachomatis (CT) 5.5% (54/986) - 1.3% (8/631) - 3.0% (13/433) 0.75 (0.62–
0.90) p=0.001
T vaginalis
2 12.3% (27/220) - - - 6.5% (7/107) 0.81 (0.62–
1.05) p=0.09
Bacterial vaginosis 48.1% (485/987) - 38.4% (246/641) - - 0.75 (0.66–
0.84) p,0.001
Pregnancy 1.09 (0.72–
1.64) p=0.69
Yes -
3 - 10.0% - 9.3%
Contraceptive prevalence 1.26 (1.17–
1.36) p,0.001
Yes (all methods) 33.9% 34.3% 35.2% 37.5% 43.3%
Contraceptive methods
Condom 6.3% 7.4% 8.4% 5.9% 9.3% 1.19 (1.05–
1.35) p=0.005
Pill/injection/IUCD 23.4% 20.4% 19.4% 21.9% 24.0% 1.10 (0.99–
1.22) p=0.08
Traditional/safe period/other 4.2% 6.6% 7.4% 9.7% 10.0% 1.44 (1.26–
1.64) p,0.001
Planning pregnancy in next three months 0.62 (0.51–
0.75) p,0.001
Yes 21.0% 14.0% 11.6% 7.4% 7.0%
Partners in past three months 1.72 (1.54–
1.92) p,0.001
Two or more 19.6% 8.9% 7.5% 6.1% 5.8%
Condom use with regular partner 1.06 (0.95–
1.17) p=0.32
Always 10.2% 12.8% 12.3% 12.1% 10.7%
Condom use with other partners 1.57 (1.28–
1.93) p,0.001
Always 34.3% 50.0% 62.7% 62.8% 57.4%
Cleaned inside vagina in past three months 1.25 (1.16–
1.34) p,0.001
Yes 73.7% 85.2% 88.1% 85.6% 83.6%
Chance of catching HIV 0.86 (0.79–
0.94) p=0.001
Likely 89.5% 87.9% 84.6% 87.7% 83.7%
1. For each variable, we modelled the change in prevalence between visits using a random-effects logistic regression model adjusting for visit as a continuous variable
and including a random intercept. This modelling approach adjusted for the expected additional correlation between multiple responses by the same participant. We
calculated formal tests of significance using likelihood ratio tests, and the p-values from these tests are presented in the final column of the table.
2. T. vaginalis sample N=220. Measurements made at recruitment (visit 1) and at 12 months (visit 5).
3. Pregnancy status was an initial study exclusion criterion. Prevalence at Visit 01 was therefore zero among eligible participants.
doi:10.1371/journal.pone.0010661.t004
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Asia[46,47,48,49,50], illustrating the considerable logistical diffi-
culties that need to be addressed when working with such study
populations. Key factors likely to have contributed to the early
losses observed in Mwanza include single clinic attendance by
women who wanted to receive STI treatment alone but who had
no intention of remaining in the study; attendance by women
curious to know more about the study having attended community
mobilization activities but who subsequently decided not to
participate further; and difficulties tracing women in the
community to remind them to re-attend clinic due to inaccuracies
in baseline locator information and high cohort mobility[26,37].
Many of these issues could have been addressed during a
preliminary screening visit to identify and exclude women who
are unlikely to re-attend, through improved participant tracing
procedures and targeted community-based mobilization and
liaison activities, all of which were subsequently successfully
incorporated into the design of the MDP301 microbicide trial in
Mwanza where 80–85% re-attendance figures were observed at
each of the scheduled 3-monthly clinical follow-up visits.
The incidence of HIV observed during the feasibility study was
lower than in a similar occupational cohort in Mbeya, Tanza-
nia[48] or among female sex workers in Kenya, South Africa,
Thailand, Benin and Cote d’Ivoire[47,51,52,53], but higher than
that observed among hotel, bar workers and women attending
family planning clinics in the HPTN055 study in Moshi, Tanzania
(HIV incidence 1.3/100PYs [95%CI:0.3–3.8]) [50]. It is difficult
however, to define a suitable cut off level for HIV incidence above
which prevention trials are likely to be feasible because in any
given at-risk study population, feasibility depends on additional
Table 5. Factors associated with re-attendance
1 among 771 eligible women attending at three months.
Characteristic Total Number % complete attendance OR (95% CI)
2 Adjusted OR (95% CI)
3
Age (years) n=770 P,0.001 ,0.001
,20 41 39.0 1 1
20–24 164 53.1 1.85 (0.98–3.49) 1.93 (1.01–3.70)
25–34 336 65.5 3.25 (1.77–5.96) 3.20 (1.71–5.99)
35+ 229 81.2 7.38 (3.83–14.24) 5.40 (2.68–10.90)
Facility type n=771 P=0.005 P=0.19
Pombe/Mamalishe 517 71.8 1 1
Guesthouse/Hotel 115 53.0 0.55 (0.37–0.83) 0.65 (0.41–1.02)
Bar/Restaurant/Grocery 139 55.4 0.64 (0.44–0.94) 0.80 (0.52–1.23)
Partners in past 3 months
4 n=766 P=0.01 P=0.08
None 124 74.2 1 1
One 505 67.5 0.81 (0.52–1.28) 0.75 (0.47–1.20)
Two 98 54.1 0.60 (0.34–1.06) 0.62 (0.34–1.12)
Three or more 39 46.2 0.45 (0.22–0.91) 0.56 (0.26–1.19)
Condom usage n=771 P=0.05 P=0.73
No partner 130 73.9 1 1
Never 466 68.5 0.88 (0.56–1.38) 1.00 (0.57 1.77)
Sometimes 116 53.5 0.58 (0.34–0.99) 0.94 (0.44–2.01)
Always 53 50.9 0.53 (0.28–1.01) 0.72 (0.34–1.54)
Travel
4, 5 n=770 P=0.01 P=0.03
Low 527 69.6 1 1
Moderate 208 58.2 0.69 (0.50–0.96) 0.73 (0.51–1.03)
High 35 57.1 0.54 (0.27–1.08) 0.54 (0.27–1.09)
Permanence
4, 6 n=771 P=0.002 P=0.01
High 342 75.2 1 1
Moderate 206 64.1 0.73 (0.50–1.08) 0.71 (0.47–1.06)
Low 221 53.4 0.56 (0.39–0.81) 0.59 (0.40–0.87)
1. Attendance was defined on a four–level [0, 1, 2 and 3] ordinal scale as the number of visits made after a second visit at 3 mo (i.e. zero, one, two, or three additional
visits) and modelled using ordinal logistic regression. The OR is the estimated odds ratio of $k visits vs ,k visits, assumed equal for all k (1,2,3). Complete attendance
was defined as attending all three possible visits after a second visit at 3-months.
2. Odds Ratio adjusted for age.
3. Odds Ratio adjusted for age, clinic site, facility type, partners in past 3 months, travel, and permanence.
4. Test for trend used to assess significance of term in ordinal logistic regression.
5. Travel in the three months preceding the first clinic visit was categorised as: Low (zero nights away from home), Moderate ($1 night but less than one continuous
week away from home) and High ($1 continuous week away from home on one or more occasions).
6. Permanence of home and workplace location was categorised as: High (lived in the same house and worked at the same facility during the past year); Moderate (lived
or worked at the same location for ,1 year and moved house no more than once in the previous year); Low (lived or worked at the same location for ,1 year and
moved house twice or more in the previous year).
doi:10.1371/journal.pone.0010661.t005
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achievable and the risk of significant losses to follow up. For
example, all of the HIV seroconversions observed in the Moshi
HPTN055 study (N=240) occurred among hotel and bar workers,
who were also significantly less likely to re-attend at 12-months
compared to women recruited from family planning clinics (81%
vs. 93%; p,0.01)[50]. Prior to the MDP301 trial in Mwanza, a
second, more intensive, participatory community mapping survey
was conducted in May 2004, which identified a total of 3581
women working in 1106 facilities. We estimated that around 30–
35% of these potential participants would be ineligible for trial
entry based on HIV and pregnancy prevalences at first visit as
described above and that an additional 20–25% would likely be
unable to enroll for other reasons such as being unwilling to
participate having attended a community-based mobilization
meeting; unable to provide informed consent; or unwilling to
receive their HIV test result prior to randomization. In addition,
there are considerable challenges in attempting to contact all
potential participants in this setting due to a variety of external
contextual factors (e.g. not at work because child sick; sleeping
following evening/night shift when fieldworkers visit the facility).
The total sample size considered achievable was hence estimated
at around 1300–1400 subjects. This essentially makes single-centre
HIV prevention trials unfeasible in this setting, particularly when
current candidate vaginal microbicides and HIV vaccines are
expected to be only partly effective. For example, to detect a 50%
effect size with 90% power at the 5% significance level in a two-
arm trial, assuming an HIV incidence of 2.0/100PYs in the
placebo arm as observed in potentially eligible women in the
feasibility study, would require a total of 6300PYs of follow-up, not
realistically achievable in this study population A more appropri-
ate design was adopted in the MDP301 trial, in which women
were recruited from six sites in four African countries, the target
for subject recruitment in Mwanza was 1150 and the individual
period of follow-up for the primary efficacy outcome was 12-
months. In addition, given the modest overall HIV incidence
observed in the Mwanza feasibility study cohort but the relatively
high incidence seen among younger women working in modern
bars and restaurants (4.1/100PYs [95%CI: 1.7–9.7]; Table 3),
recruitment strategies to the MDP301 trial in Mwanza focused on
women in this sub-population who appeared to be at greatest risk
of HIV sero-conversion.
There was some evidence of differential loss to follow up during
the feasibility study: younger, more mobile, arguably ‘higher-risk’
women were less likely to re-attend. In addition there were
significant reductions in reported numbers of sexual partners and
the prevalence of laboratory-confirmed STIs and vaginal infec-
tions observed and an increase in reported condom use with non-
regular partners. An alternative explanation is that these findings
are the result of effective clinical services for STI management and
risk reduction counselling, as reported in similar studies else-
where[48,53]. Social desirability bias may also have played some
role in modifying reported sexual behaviour over the period of
follow-up. Whatever the explanations, our findings suggest that
there may be a tension between recruiting ‘higher-risk’ women
with higher HIV incidence to reduce sample size requirements,
and the need to maintain high rates of follow-up.
Pregnancy rates were relatively high during the feasibility study
but lower than those observed in some other at-risk cohorts, for
example, among female sex workers in Madagascar, where an
incidence of 53 pregnancies per 100PYs has been reported[43].
Low contraceptive prevalence and the lack of predictive value of
stated intent to become pregnant are also cause for concern and
represent a major risk to the successful conduct and completion of
any future microbicide trial in this setting. In order to minimise
this risk during the MDP301 trial, potential participants were
advised in community meetings and during informed consent
procedures that they should only consider enrolment if they were
willing to forgo further pregnancies during the trial; that they
should not enrol if they were considering pregnancy in the next 6–
12 months; and that they should consider using highly effective
family planning methods such as long-acting intramuscular
progesterone, oral contraceptive pill or the intra-uterine contra-
ceptive device (IUCD). These strategies were partly successful: in
the first 18-months of the main phase III trial in Mwanza, the
incidence of pregnancy was 12.3/100PYs (95%CI:8.9–17.0), far
lower than that observed during this feasibility study.
In addition to the epidemiological considerations above there
are a range of other factors that contribute to feasibility,
principally ethical considerations; a full discussion of which is
beyond the scope of this paper but which are described in detail
elsewhere[26]. The prevalence and nature of intravaginal
practices are also important since internal cleansing and the use
of vaginal inserts such as herb poultices could have a significant
impact on the apparent efficacy of a future trial product,
particularly if these are carried out immediately before or after
sex when they may inactivate or remove the candidate microbicide
under investigation. In Mwanza, detailed quantitative and
qualitative research was conducted during the feasibility study in
order to better understand the nature, timing and different types of
intravaginal practices prevalent in this setting (Allen C et al,
submitted, October 2009).
The Mwanza feasibility study data suggest that women working
in food and recreational facilities in Tanzania and other parts of
sub-Saharan Africa are likely to be suitable study populations for
microbicide and other HIV prevention trials. Effective locally-
appropriate strategies to address high pregnancy rates and early
losses to follow-up are essential to minimise risk to clinical trials in
these settings.
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